The Decrease in Prolidase Activity in Myeloproliferative Neoplasms

作者：Nowicka Jadwiga^*; Nahaczewska Wieslawa; Owczarek Henryk; Wozniak Mieczyslaw

来源：Advances in Clinical and Experimental Medicine, 2012, 21(6): 767-771.

• collagen
• markers of bone metabolism
• prolidase
• myeloproliferative neoplasms

Backgraound. The development of bone marrow fibrosis is a severe complication in hematological diseases. The progress of bone marrow myelofibrosis is evaluated by a trephine examination and may be characterized by the biochemical markers of collagen turnover determination. %26lt;br%26gt;Objectives. Investigation of serum prolidase activity and biochemical markers of collagen metabolism in order to establish its role in the development of bone marrow fibrosis. %26lt;br%26gt;Material and Methods. The group of 37 patients with myeloproliferative neoplasms (MPN) before treatment, consisted of 16 patients with chronic myeloid leukemia (CML), 7 with primary myelofibrosis (PMF), 8 with essential thrombocythopenia (ET), and 6 with polycythemia vera (PV). %26lt;br%26gt;Results. It was found that the plasma activity of prolidase (Pro) was reduced to almost half together with the serum level of osteocalcin (BGL), and hydroxyproline (H-PRO) in the serum and urine of patients with MPN in comparison to the control group. In the MPN group of patients, the levels of N-terminal procollagen III peptide (PIIINP), type I procollagen (PICP) and the C-terminal telopeptide of type I collagen (ICTP) were significantly higher. %26lt;br%26gt;Conclusions. The alteration of collagen turnover markers in the MPN patient group (the elevation of synthesis and inhibition of collagen catabolism rate) has suggested that a diminished prolidase activity may contribute to such alteration of collagen metabolism and should be consider a biomarker of MPN progress (Adv Clin Exp Med 2012, 21, 6, 767-771).

• 出版日期2012